Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

González-Barca E, Boumendil A, Blaise D, Trněný M, Masszi T, Finel H, Michieli MG, Bittenbring JT, Gritti G, Snowden JA, Bishton M, Bruno B, de Villambrosia SG, Janikova A, Leleu X, Anagnostopoulos A, Poiré X, Crysandt M, Özkurt ZN, Vandenberghe E, Itälä-Remes M, Cahn JY, Jantunen E, Schroyens W, Maertens J, Esquirol A, Dreger P, Montoto S, Sureda A.

Bone Marrow Transplant. 2019 Sep 20. doi: 10.1038/s41409-019-0650-x. [Epub ahead of print]

PMID:
31541205
2.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N.

Biol Blood Marrow Transplant. 2019 Jul 6. pii: S1083-8791(19)30436-7. doi: 10.1016/j.bbmt.2019.07.004. [Epub ahead of print]

PMID:
31288095
3.

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM.

J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.

PMID:
31112476
4.

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.

Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M.

Ann Hematol. 2019 Aug;98(8):1961-1972. doi: 10.1007/s00277-019-03694-y. Epub 2019 May 8.

PMID:
31065733
5.

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.

Klanova M, Oestergaard MZ, Trněný M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G.

Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.

PMID:
31053601
6.

First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter.

Belohlavkova P, Steinerova K, Karas M, Skoumalova I, Rohon P, Indrak K, Voglova J, Vrbacky F, Cmunt E, Necasova T, Kristkova Z, Trneny M, Zak P, Papajik T, Faber E.

Leuk Res. 2019 Jun;81:67-74. doi: 10.1016/j.leukres.2019.04.011. Epub 2019 Apr 24.

PMID:
31051328
7.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.

Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.

PMID:
31004002
8.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators.

J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.

PMID:
30897038
9.

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.

Špaček M, Obrtlíková P, Hrobková S, Cmunt E, Karban J, Molinský J, Šimkovič M, Mociková H, Mohammadová L, Panovská A, Novák J, Trněný M, Smolej L, Doubek M.

Leuk Res. 2019 Apr;79:17-21. doi: 10.1016/j.leukres.2019.02.002. Epub 2019 Feb 15.

PMID:
30797139
10.

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.

Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M.

Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.

11.

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, Campr V, Prochazka V, Obr A, Jaksa R, Kuntscherova J, Boudová L, Kodet R, Janikova A, Trneny M.

Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13. No abstract available.

PMID:
30474171
12.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.

13.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW.

Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1.

PMID:
30389036
14.

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M.

Blood. 2018 Nov 29;132(22):2389-2400. doi: 10.1182/blood-2018-06-855502. Epub 2018 Sep 13.

PMID:
30213873
15.

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.

Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, Duras J, Mocikova H, Trneny M.

Leuk Res. 2018 Oct;73:29-38. doi: 10.1016/j.leukres.2018.08.019. Epub 2018 Aug 31.

PMID:
30195062
16.

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry.

Obr A, Prochazka V, Papajik T, Klener P Jr, Janikova A, Salek D, Belada D, Pytlík R, Sykorova A, Mocikova H, Simkovic M, Campr V, Dlouha J, Furst T, Trněný M.

Leuk Lymphoma. 2019 Mar;60(3):748-755. doi: 10.1080/10428194.2018.1508672. Epub 2018 Sep 6.

PMID:
30188225
17.

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M.

Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13.

PMID:
30129045
18.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

19.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

PMID:
29584548
20.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748.

21.

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M.

Leukemia. 2018 Aug;32(8):1799-1803. doi: 10.1038/s41375-018-0023-2. Epub 2018 Feb 2. No abstract available.

22.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

23.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N.

Biol Blood Marrow Transplant. 2018 May;24(5):930-936. doi: 10.1016/j.bbmt.2018.01.006. Epub 2018 Jan 12.

24.

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.

Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M.

Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9.

PMID:
29318369
25.

Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.

Lokvenc M, Kalinova M, Forsterova K, Klener P, Trneny M, Fronkova E, Kodet R.

Ann Hematol. 2018 Mar;97(3):467-474. doi: 10.1007/s00277-017-3210-8. Epub 2017 Dec 22.

PMID:
29273915
26.

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma.

Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trnený M, Wedding U, Fields P; ESMO Lymphoma Consensus Conference Panel Members.

Ann Oncol. 2018 Mar 1;29(3):544-562. doi: 10.1093/annonc/mdx413.

PMID:
29194473
27.

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trnĕný M; SPRINT Trial Investigators.

Br J Haematol. 2018 Jan;180(2):224-235. doi: 10.1111/bjh.15025. Epub 2017 Nov 28.

28.

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.

Dreyling M, Aurer I, Cortelazzo S, Hermine O, Hess G, Jerkeman M, Le Gouill S, Ribrag V, Trněný M, Visco C, Walewski J, Zaja F, Zinzani PL.

Leuk Lymphoma. 2018 Aug;59(8):1814-1828. doi: 10.1080/10428194.2017.1403602. Epub 2017 Nov 27. Review.

PMID:
29172868
29.

Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female.

Patzelt M, Zarubova L, Klener P, Barta J, Benkova K, Brandejsova A, Trneny M, Gürlich R, Sukop A.

Aesthetic Plast Surg. 2018 Apr;42(2):451-455. doi: 10.1007/s00266-017-1012-y. Epub 2017 Nov 3.

PMID:
29101436
30.

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.

Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30.

PMID:
29083050
31.

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.

Dusílková N, Bašová P, Polívka J, Kodet O, Kulvait V, Pešta M, Trněný M, Stopka T.

Int J Mol Sci. 2017 Oct 15;18(10). pii: E2136. doi: 10.3390/ijms18102136.

32.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17.

33.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W.

N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.

34.

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH.

J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10.

PMID:
28796588
35.

MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia.

Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M, Stopka T.

Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63. No abstract available.

36.

[The Importance of MicroRNA Deregulation in the Molecular Pathogenesis and Histological Transformation of Follicular Lymphoma].

Musilová K, Deván J, Zlámalíková L, Křen L, Móciková H, Procházka V, Mayer J, Trněný M, Janíková A, Mráz M.

Klin Onkol. Spring 2017;30(Supplementum1):163-165. Czech.

PMID:
28471196
37.

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID.

Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. doi: 10.1158/1078-0432.CCR-16-2818. Epub 2017 Apr 5.

38.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

39.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867.

40.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

PMID:
28202458
41.

Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement.

Maswabi BC, Molinsky J, Savvulidi F, Zikmund T, Prukova D, Tuskova D, Klanova M, Vockova P, Lateckova L, Sefc L, Zivny J, Trneny M, Klener P.

Haematologica. 2017 Apr;102(4):e152-e155. doi: 10.3324/haematol.2016.151571. Epub 2017 Jan 5. No abstract available.

42.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

43.

Efficacy and safety of human mesenchymal stromal cells in healing of critical-size bone defects in immunodeficient rats.

Pytlík R, Rentsch C, Soukup T, Novotný L, Rentsch B, Kanderová V, Rychtrmocová H, Kalmárová M, Stehlík D, Trněný M, Slanař O.

Physiol Res. 2017 Mar 31;66(1):113-123. Epub 2016 Oct 26.

44.

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.

Procházka V, Papajík T, Janíková A, Belada D, Kozák T, Šálek D, Sýkorová A, Móciková H, Campr V, Dlouhá J, Langová K, Fürst T, Trněný M.

Leuk Lymphoma. 2017 Mar;58(3):601-613. doi: 10.1080/10428194.2016.1213834. Epub 2016 Sep 25.

PMID:
27666539
45.

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.

Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T.

Blood Cancer J. 2016 Sep 23;6(9):e475. doi: 10.1038/bcj.2016.80. No abstract available.

46.

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Dührsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C.

Bone Marrow Transplant. 2017 Feb;52(2):216-221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19.

PMID:
27643872
47.

[Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)].

Sýkorová A, Pytlík R, Móciková H, Belada D, Benešová K, Papajík T, Janíková A, Šálek D, Procházka V, Vokurka S, Campr V, Klener P, Kubáčková K, Trněný M.

Klin Onkol. 2016;29(4):295-302. Czech.

PMID:
27534788
48.

Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model.

Klanova M, Soukup T, Molinsky J, Lateckova L, Vockova P, Alam M, Zivny J, Trneny M, Klener P.

Neoplasma. 2016;63(5):774-8. doi: 10.4149/neo_2016_515.

PMID:
27468882
49.

The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study.

Valkova V, Jircikova J, Trnkova M, Steinerova K, Keslova P, Lanska M, Koristek Z, Raida L, Krejci M, Kruntoradova K, Dolezal T, Benesova K, Cetkovsky P, Trneny M.

Neoplasma. 2016;63(5):743-51. doi: 10.4149/neo_2016_511.

PMID:
27468878
50.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.

Supplemental Content

Loading ...
Support Center